Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

What Makes a Kinase Promiscuous for Inhibitors?

Hanson SM, Georghiou G, Thakur MK, Miller WT, Rest JS, Chodera JD, Seeliger MA.

Cell Chem Biol. 2018 Dec 11. pii: S2451-9456(18)30412-4. doi: 10.1016/j.chembiol.2018.11.005. [Epub ahead of print]

PMID:
30612951
2.

More Diversity Yields a Clearer Picture into the Architecture of the Protein Kinase Domain.

Seeliger MA.

Cell Syst. 2018 Oct 24;7(4):356-357. doi: 10.1016/j.cels.2018.10.002.

PMID:
30359621
3.

KA1 Domains: Unity in Mechanistic Diversity.

Paung Y, Seeliger MA.

Structure. 2018 Aug 7;26(8):1045-1047. doi: 10.1016/j.str.2018.07.002.

PMID:
30089246
4.

An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression.

Albanese SK, Parton DL, Işık M, Rodríguez-Laureano L, Hanson SM, Behr JM, Gradia S, Jeans C, Levinson NM, Seeliger MA, Chodera JD.

Biochemistry. 2018 Aug 7;57(31):4675-4689. doi: 10.1021/acs.biochem.7b01081. Epub 2018 Jul 26.

PMID:
30004690
5.

Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites.

Tong M, Pelton JG, Gill ML, Zhang W, Picart F, Seeliger MA.

Nat Commun. 2017 Dec 18;8(1):2160. doi: 10.1038/s41467-017-02240-6.

6.

Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions.

Alford VM, Kamath A, Ren X, Kumar K, Gan Q, Awwa M, Tong M, Seeliger MA, Cao J, Ojima I, Sampson NS.

ACS Chem Biol. 2017 Nov 17;12(11):2788-2803. doi: 10.1021/acschembio.7b00758. Epub 2017 Oct 10.

7.

Measuring Phospholipase D Enzymatic Activity Through Biochemical and Imaging Methods.

Philip F, Ha EE, Seeliger MA, Frohman MA.

Methods Enzymol. 2017;583:309-325. doi: 10.1016/bs.mie.2016.09.041. Epub 2016 Oct 22.

8.

Enzymatic Activity and Thermodynamic Stability of Biliverdin IXβ Reductase Are Maintained by an Active Site Serine.

Chu WT, Nesbitt NM, Gnatenko DV, Li Z, Zhang B, Seeliger MA, Browne S, Mantle TJ, Bahou WF, Wang J.

Chemistry. 2017 Feb 3;23(8):1891-1900. doi: 10.1002/chem.201604517. Epub 2017 Jan 11.

9.

Dynamically Coupled Residues within the SH2 Domain of FYN Are Key to Unlocking Its Activity.

Huculeci R, Cilia E, Lyczek A, Buts L, Houben K, Seeliger MA, van Nuland N, Lenaerts T.

Structure. 2016 Nov 1;24(11):1947-1959. doi: 10.1016/j.str.2016.08.016. Epub 2016 Sep 29.

10.

Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles.

Aleem S, Georghiou G, Kleiner RE, Guja K, Craddock BP, Lyczek A, Chan AI, Garcia-Diaz M, Miller WT, Liu DR, Seeliger MA.

Cell Chem Biol. 2016 Sep 22;23(9):1103-1112. doi: 10.1016/j.chembiol.2016.07.017. Epub 2016 Sep 1.

11.

A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems.

Lebedev I, Nemajerova A, Foda ZH, Kornaj M, Tong M, Moll UM, Seeliger MA.

J Mol Biol. 2016 Oct 9;428(20):4154-4167. doi: 10.1016/j.jmb.2016.08.001. Epub 2016 Aug 8.

12.

Structural and Functional Analysis of the Allosteric Inhibition of IRE1α with ATP-Competitive Ligands.

Feldman HC, Tong M, Wang L, Meza-Acevedo R, Gobillot TA, Lebedev I, Gliedt MJ, Hari SB, Mitra AK, Backes BJ, Papa FR, Seeliger MA, Maly DJ.

ACS Chem Biol. 2016 Aug 19;11(8):2195-205. doi: 10.1021/acschembio.5b00940. Epub 2016 Jun 9.

13.

Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.

Kwarcinski FE, Brandvold KR, Phadke S, Beleh OM, Johnson TK, Meagher JL, Seeliger MA, Stuckey JA, Soellner MB.

ACS Chem Biol. 2016 May 20;11(5):1296-304. doi: 10.1021/acschembio.5b01018. Epub 2016 Mar 1.

PMID:
26895387
14.

A dynamically coupled allosteric network underlies binding cooperativity in Src kinase.

Foda ZH, Shan Y, Kim ET, Shaw DE, Seeliger MA.

Nat Commun. 2015 Jan 20;6:5939. doi: 10.1038/ncomms6939.

15.

Targeting conformational plasticity of protein kinases.

Tong M, Seeliger MA.

ACS Chem Biol. 2015 Jan 16;10(1):190-200. doi: 10.1021/cb500870a. Epub 2014 Dec 19. Review.

PMID:
25486330
16.

Kinase inhibitors: an allosteric add-on.

Foda ZH, Seeliger MA.

Nat Chem Biol. 2014 Oct;10(10):796-7. doi: 10.1038/nchembio.1630. Epub 2014 Sep 7. No abstract available.

PMID:
25195010
17.

Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.

Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, Tang WJ, Charron MJ, Seeliger MA, Saghatelian A, Liu DR.

Nature. 2014 Jul 3;511(7507):94-8. doi: 10.1038/nature13297. Epub 2014 May 21.

18.

A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.

Etheridge SL, Cosgrove ME, Sangkhae V, Corbo LM, Roh ME, Seeliger MA, Chan EL, Hitchcock IS.

Blood. 2014 Feb 13;123(7):1059-68. doi: 10.1182/blood-2012-12-473777. Epub 2013 Dec 31.

19.

Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.

Hari SB, Perera BG, Ranjitkar P, Seeliger MA, Maly DJ.

ACS Chem Biol. 2013 Dec 20;8(12):2734-43. doi: 10.1021/cb400663k. Epub 2013 Oct 29.

20.

p73 - constitutively open for business.

Seeliger MA, Moll UM.

Cell Death Differ. 2013 Aug;20(8):972-3. doi: 10.1038/cdd.2013.56. No abstract available.

21.

Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors.

Wang L, Perera BG, Hari SB, Bhhatarai B, Backes BJ, Seeliger MA, Schürer SC, Oakes SA, Papa FR, Maly DJ.

Nat Chem Biol. 2012 Dec;8(12):982-9. doi: 10.1038/nchembio.1094. Epub 2012 Oct 21.

22.

Analysis of DEAD-box proteins in mRNA export.

Montpetit B, Seeliger MA, Weis K.

Methods Enzymol. 2012;511:239-54. doi: 10.1016/B978-0-12-396546-2.00011-5.

PMID:
22713323
23.

Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles.

Georghiou G, Kleiner RE, Pulkoski-Gross M, Liu DR, Seeliger MA.

Nat Chem Biol. 2012 Feb 19;8(4):366-74. doi: 10.1038/nchembio.792.

24.

How does a drug molecule find its target binding site?

Shan Y, Kim ET, Eastwood MP, Dror RO, Seeliger MA, Shaw DE.

J Am Chem Soc. 2011 Jun 22;133(24):9181-3. doi: 10.1021/ja202726y. Epub 2011 May 13. Erratum in: J Am Chem Soc. 2014 Feb 26;136(8):3320.

25.

Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.

Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J.

Mol Cell. 2011 Apr 8;42(1):9-22. doi: 10.1016/j.molcel.2011.03.004. Review.

26.

A conserved mechanism of DEAD-box ATPase activation by nucleoporins and InsP6 in mRNA export.

Montpetit B, Thomsen ND, Helmke KJ, Seeliger MA, Berger JM, Weis K.

Nature. 2011 Apr 14;472(7342):238-42. doi: 10.1038/nature09862. Epub 2011 Mar 27.

27.

N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor.

Choi Y, Seeliger MA, Panjarian SB, Kim H, Deng X, Sim T, Couch B, Koleske AJ, Smithgall TE, Gray NS.

J Biol Chem. 2009 Oct 16;284(42):29005-14. doi: 10.1074/jbc.M109.026633. Epub 2009 Aug 13.

28.

A MAPK scaffold lends a helping hand.

Seeliger MA, Kuriyan J.

Cell. 2009 Mar 20;136(6):994-6. doi: 10.1016/j.cell.2009.03.002.

29.

Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.

Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ.

Cancer Res. 2009 Mar 15;69(6):2384-92. doi: 10.1158/0008-5472.CAN-08-3953. Epub 2009 Mar 10.

30.

Comparative analysis of mutant tyrosine kinase chemical rescue.

Muratore KE, Seeliger MA, Wang Z, Fomina D, Neiswinger J, Havranek JJ, Baker D, Kuriyan J, Cole PA.

Biochemistry. 2009 Apr 21;48(15):3378-86. doi: 10.1021/bi900057g.

31.

A conserved protonation-dependent switch controls drug binding in the Abl kinase.

Shan Y, Seeliger MA, Eastwood MP, Frank F, Xu H, Jensen MØ, Dror RO, Kuriyan J, Shaw DE.

Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):139-44. doi: 10.1073/pnas.0811223106. Epub 2008 Dec 24.

32.

Tuning a three-component reaction for trapping kinase substrate complexes.

Statsuk AV, Maly DJ, Seeliger MA, Fabian MA, Biggs WH 3rd, Lockhart DJ, Zarrinkar PP, Kuriyan J, Shokat KM.

J Am Chem Soc. 2008 Dec 24;130(51):17568-74. doi: 10.1021/ja807066f.

33.

Activation of tyrosine kinases by mutation of the gatekeeper threonine.

Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ.

Nat Struct Mol Biol. 2008 Oct;15(10):1109-18. doi: 10.1038/nsmb.1486. Epub 2008 Sep 14.

34.

Structural basis for the recognition of c-Src by its inactivator Csk.

Levinson NM, Seeliger MA, Cole PA, Kuriyan J.

Cell. 2008 Jul 11;134(1):124-34. doi: 10.1016/j.cell.2008.05.051.

35.

c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.

Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J.

Structure. 2007 Mar;15(3):299-311.

36.

Activation of ubiquitin ligase SCF(Skp2) by Cks1: insights from hydrogen exchange mass spectrometry.

Yao ZP, Zhou M, Kelly SE, Seeliger MA, Robinson CV, Itzhaki LS.

J Mol Biol. 2006 Oct 27;363(3):673-86. Epub 2006 Aug 16.

PMID:
16979657
37.

Folding and fibril formation of the cell cycle protein Cks1.

Bader R, Seeliger MA, Kelly SE, Ilag LL, Meersman F, Limones A, Luisi BF, Dobson CM, Itzhaki LS.

J Biol Chem. 2006 Jul 7;281(27):18816-24. Epub 2006 May 4.

38.

High yield bacterial expression of active c-Abl and c-Src tyrosine kinases.

Seeliger MA, Young M, Henderson MN, Pellicena P, King DS, Falick AM, Kuriyan J.

Protein Sci. 2005 Dec;14(12):3135-9. Epub 2005 Oct 31.

39.

Role of conformational heterogeneity in domain swapping and adapter function of the Cks proteins.

Seeliger MA, Spichty M, Kelly SE, Bycroft M, Freund SM, Karplus M, Itzhaki LS.

J Biol Chem. 2005 Aug 26;280(34):30448-59. Epub 2005 Mar 16.

40.

Mechanism of CDK5/p25 binding by CDK inhibitors.

Mapelli M, Massimiliano L, Crovace C, Seeliger MA, Tsai LH, Meijer L, Musacchio A.

J Med Chem. 2005 Feb 10;48(3):671-9.

PMID:
15689152
41.

Cooperative organization in a macromolecular complex.

Seeliger MA, Breward SE, Friedler A, Schon O, Itzhaki LS.

Nat Struct Biol. 2003 Sep;10(9):718-24. Epub 2003 Aug 3. Erratum in: Nat Struct Biol. 2004 Jul;11(7):678.

PMID:
12897769
42.

Weak cooperativity in the core causes a switch in folding mechanism between two proteins of the cks family.

Seeliger MA, Breward SE, Itzhaki LS.

J Mol Biol. 2003 Jan 3;325(1):189-99.

PMID:
12473461
43.

Three different binding sites of Cks1 are required for p27-ubiquitin ligation.

Sitry D, Seeliger MA, Ko TK, Ganoth D, Breward SE, Itzhaki LS, Pagano M, Hershko A.

J Biol Chem. 2002 Nov 1;277(44):42233-40. Epub 2002 Jul 24.

44.

Folding and association of the human cell cycle regulatory proteins ckshs1 and ckshs2.

Seeliger MA, Schymkowitz JW, Rousseau F, Wilkinson HR, Itzhaki LS.

Biochemistry. 2002 Jan 29;41(4):1202-10.

PMID:
11802719

Supplemental Content

Loading ...
Support Center